- Home
- SWIM vs EYPT Comparison
SWIM vs EYPT Comparison
Compare SWIM & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SWIM
- EYPT
- Stock Information
- Founded
- SWIM 1956
- EYPT 1987
- Country
- SWIM United States
- EYPT United States
- Employees
- SWIM N/A
- EYPT N/A
- Industry
- SWIM Plastic Products
- EYPT Biotechnology: Laboratory Analytical Instruments
- Sector
- SWIM Industrials
- EYPT Industrials
- Exchange
- SWIM Nasdaq
- EYPT Nasdaq
- Market Cap
- SWIM 678.4M
- EYPT 579.4M
- IPO Year
- SWIM 2021
- EYPT 2005
- Fundamental
- Price
- SWIM $6.97
- EYPT $10.20
- Analyst Decision
- SWIM Hold
- EYPT Strong Buy
- Analyst Count
- SWIM 4
- EYPT 8
- Target Price
- SWIM $6.70
- EYPT $24.75
- AVG Volume (30 Days)
- SWIM 570.3K
- EYPT 753.7K
- Earning Date
- SWIM 08-05-2025
- EYPT 08-06-2025
- Dividend Yield
- SWIM N/A
- EYPT N/A
- EPS Growth
- SWIM N/A
- EYPT N/A
- EPS
- SWIM N/A
- EYPT N/A
- Revenue
- SWIM $509,311,000.00
- EYPT $56,042,000.00
- Revenue This Year
- SWIM $9.24
- EYPT N/A
- Revenue Next Year
- SWIM $5.86
- EYPT N/A
- P/E Ratio
- SWIM N/A
- EYPT N/A
- Revenue Growth
- SWIM N/A
- EYPT 12.04
- 52 Week Low
- SWIM $2.91
- EYPT $3.91
- 52 Week High
- SWIM $8.41
- EYPT $13.99
- Technical
- Relative Strength Index (RSI)
- SWIM 59.22
- EYPT 59.49
- Support Level
- SWIM $5.95
- EYPT $10.26
- Resistance Level
- SWIM $7.08
- EYPT $11.00
- Average True Range (ATR)
- SWIM 0.28
- EYPT 0.65
- MACD
- SWIM 0.02
- EYPT -0.06
- Stochastic Oscillator
- SWIM 85.84
- EYPT 46.43
About SWIM Latham Group Inc.
Latham Group Inc is a designer, manufacturer, and marketer of in-ground residential swimming pools, liners, and covers in North America, Australia, and New Zealand. It derives a majority of its revenue from the United States.
About EYPT EyePoint Pharmaceuticals Inc.
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.